BSE Announcement

The Board of A-1 at the meeting held on 14th November 2025 discussed the matter of dividend and declared it will be considered and reviewed in upcoming quarters.

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.

The board of Allcargo Logistics at its meeting held on 14 November 2025 has approved the following changes:

Cessation of:
- Adarsh Sudhakar Hegde – Managing Director (DIN: 00035040)
- Ravi Jakhar – Chief Financial Officer (Continue to be the Group CFO & Director – Strategy)
- Swati Singh – Company Secretary & Compliance Officer

Appointment of:
- Ketan Nishikant Kulkarni (DIN: 10735941) – Managing Director & CEO
- Deepak Jagdish Pareek – Chief Financial Officer
- Shekhar R. Singh – Company Secretary & Compliance Officer

Altius Telecom Infrastructure Trust will hold a meeting of the Board of Directors of the Company on 19 November 2025.

Ambo Agritec has postponed the meeting of the Board of Directors which was scheduled to be held on 14 November 2025. The meeting will now be held on 19 November 2025.

Bharat Global Developers has postponed the meeting of the Board of Directors which was scheduled to be held on 14 November 2025. The meeting will now be held on 20 November 2025.

Binny has revised the meeting of the Board of Directors which was scheduled to be held on 15 November 2025. The meeting will now be held on 22 November 2025.

Catvision announced that the Board of Directors of the Company at its meeting held on 14 November 2025, inter alia, have recommended the interim dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.

Dipna Pharmachem has revised the meeting of the Board of Directors which was scheduled to be held on 14 November 2025. The meeting will now be held on 19 November 2025.

Divine Power Energy announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 8 December 2025.